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Abstract: Directed enzyme prodrug therapy (DEPT) involves the delivery of a prodrug-activating 11 
enzyme to a solid tumour site, followed by the subsequent activation of an administered prodrug. 12 
One of the most studied enzyme-prodrug combinations is the nitroreductase from E. coli (NfnB) 13 
with the prodrug CB1954 [5-(aziridin-1-yl)-2,4-dinitro-benzamide]. One of the major issues faced by 14 
DEPT is the ability to successfully internalize the enzyme into the target cells. NfnB has previously 15 
been genetically modified to contain cysteine residues (NfnB-Cys) which bind to gold nanoparticles 16 
for a novel DEPT therapy called magnetic nanoparticle directed enzyme prodrug therapy 17 
(MNDEPT). One cellular internalisation method is the use of cell penetrating peptides (CPPs), which 18 
aid cellular internalization of cargo. Here the cell penetrating peptides: HR9 and Pep-1 were tested 19 
for their ability to conjugate with NfnB-Cys. The conjugates were further tested for their potential 20 
use in MNDEPT, as well as conjugating with the delivery vector intended for use in MNDEPT and 21 
tested for the vectors capability to penetrate into cells. 22 
Keywords: Nitroreductase, Cell penetrating peptide, Prodrug therapy, Darkfield imaging, 23 
Nanoparticle 24 
 25 
1. Introduction 26 
The ability of materials to traverse  the cell membrane is an important factor that has to be taken 27 
into consideration when devising new medical treatments, requiring careful engineering to aid in 28 
target cell uptake [1]. One of the most common forms of cell internalisation for molecular cargoes is 29 
endocytosis. This process generally involves the formation of a vesicle surrounding the cargo, which 30 
is then engulfed into the cell [2]. However, contents within the vesicle/ endosome are often moved 31 
into the endo-lysosomal system and are digested by acid hydrolases [3], rendering the cargo unusable 32 
for its desired function. While this process is ideal for the uptake of nutrients and for the protection 33 
of cells from antigens and toxins [4], it places a restriction on the therapeutic potential of novel 34 
therapies. As such, it is important to discover novel approaches to efficiently enable target cell uptake, 35 
for which CPPs (cell penetrating peptides) represent one solution. CPPs are short peptides [5], often 36 
no more than 30 amino acids in length [6]. Some CPPs possess the ability to pass through the cell 37 
membrane and bypass the endosomal system, leaving cargoes intact [7]. It is often reported that there 38 
are several properties that CPPs possess which enable them to efficiently pass into cells including: 39 
being rich in arginine and/or tryptophan residues [8-10], and possessing an overall positive charge at 40 
physiological pH (~7.4) [10]. CPPs have already been shown to deliver a wide range of cargo into 41 
cells, including: nucleic acids [11], proteins [12] and nanoparticles [13].  42 
DEPT has previously been explored as an emerging form of cancer treatment [14–20]. DEPT 43 
involves the delivery of a prodrug activating enzyme to a solid tumour site, whereby after cell 44 
J. Funct. Biomater. 2019, 10, x FOR PEER REVIEW 2 of 17 
 
internalisation of the enzyme, a prodrug is then administered. One of the most studied 45 
nitroreductase-prodrug combination is NfnB from E.coli K-12, used in combination with the prodrug; 46 
CB1954 (5-(aziridine-1-yl)-2,4-dinitrobenzene). NfnB converts CB1954  into either of the toxic 2’- or 47 
4’-hydroxylamine derivatives, with this combination having had a previous promising clinical 48 
outcome [21]. A range of strategies have been investigated to directly deliver the enzyme or the 49 
encoding DNA to the target site, including: viruses (VDEPT) [22,23], antibodies (ADEPT) [24], 50 
peptides [25], and cationic lipids [26]. We have investigated a novel form of DEPT that involves the 51 
incorporation of gold coated superparamagnetic iron oxide nanoparticles (AuMNP) as the delivery 52 
vehicle used to direct the enzyme to the tumour site, an approach termed magnetic nanoparticle 53 
directed enzyme prodrug therapy (MNDEPT). [14,27] A genetically modified nitroreductase (NfnB-54 
Cys) is conjugated to the surface of the nanoparticles [14,28] with conjugates already proven to retain 55 
their prodrug reducing capability [29].  56 
However, it has not yet been established whether the NfnB-Cys enzyme could be conjugated to 57 
a CPP to enhance target cell uptake, while retaining the reduction activity of CB1954. For these 58 
experiments two CPPs were chosen (HR9 and Pep-1) for conjugation to NfnB-Cys to assess cellular 59 
uptake. Both CPPs have been shown to conjugate to peptides and protein structures, improving 60 
internalization [30–33]. It was anticipated that the same improved internalization effect would be 61 
seen with NfnB-Cys. The aims of this work were to assess conjugation of the CPPs onto NfnB-Cys, 62 
and what effects this had on the enzymes activity and ability to reduce the CB1954 prodrug and cause 63 
cell death. Further to this was to conjugate NfnB-Cys and the CPPs onto magnetic nanoparticles 64 
intended for use in MNDEPT and again test for the ability for the NfnB-Cys to reduce CB1954 causing 65 
cell death. 66 
2. Results 67 
2.1. NfnB-Cys expression and purification 68 
The NfnB enzyme is native to E.coli, but has been genetically modified by our research group to 69 
contain 6 cys-tags on the N-terminus of the protein [14]. The 6 cys-tags aid the in the covalent binding 70 
of the NfnB-Cys onto gold nanoparticles [14,28]. The gene was cloned into the pET28a(+) vector, 71 
which added an additional 6 histidine residues after the cys-tag for downstream purification of the 72 
protein using metal ion affinity chromatography (IMAC). The SDS-PAGE gel of the purification is 73 
presented in figure 1, where the NfnB-Cys enzyme, eluted strongly between 300-800 mM imidazole, 74 
with the highest concentration being the 500 mM fraction. Due to the high concentration of protein, 75 
both monomeric and dimeric units were seen at ~27.3 kDa and 54.6 kDa. The NfnB-Cys enzyme was 76 
obtained at a yield of up to 5 mg/ml. 77 
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Figure 1. SDS-PAGE gel of the NfnB-Cys purification using IMAC: lane 1, protein ladder 79 
(Thermoscientific PageRuler 15-170 kDa); lane 2, flow through after applying supernatant to column; 80 
lane 3, flow through after applying 10 mM imidazole to column; lane 4, 50 mM imidazole eluent; lane 81 
5, 100 mM imidazole eluent; lane 6, 200 mM imidazole eluent; lane 7, 300 mM imidazole eluent; lane 82 
8, 500 mM imidazole eluent; lane 9, 800 mM imidazole eluent; lane 10, 1,000 mM imidazole eluent. 83 
2.2. Conjugation of HR9 and Pep-1 to NfnB-Cys 84 
CPPs can be non-covalently conjugated to a wide range of materials [30,32–38]. One of the aims 85 
of this work was to attempt to improve the cellular uptake of the NfnB-Cys into cells, conjugation of 86 
CPPs onto the NfnB-Cys could aid in this process. CPPs were conjugated onto the NfnB-Cys at 87 
varying ratios. A further aim is to conjugate the NfnB-Cys onto AuMNPs which act as the delivery 88 
vector for our DEPT method, however it needed to be established if the CPPs could interact with the 89 
NfnB-Cys without causing any negative effect. To look for proof of binding of the CPPs HR9 and 90 
Pep-1 to NfnB-Cys, native agarose (1%) gels were performed, with images of the stained gels shown 91 
in figure 2 with the free NfnB-Cys, free CPP and NfnB-Cys:CPP conjugate migration through the gels 92 
being analysed. A common feature of many CPPs is their cationic charge, therefore if the CPPs bind 93 
to the NfnB-Cys, the charge will differ from that of free NfnB-Cys, with the conjugates differently 94 
migrating through the agarose gel. As seen in figure 2 (A), HR9 is positively charged shown by 95 
migration towards the anode, whilst free NfnB-Cys is negative shown by migration towards to the 96 
cathode. Migration of the NfnB-cys-HR9 conjugates is retarded through the gel resulting in a streaked 97 
pattern. Similarly, as seen in figure 2 (B), the Pep-1 CPP is also positively charged and migrates to the 98 
anode, whilst the NfnB-Cys:Pep-1 conjugates, are again retarded through the gel, particularly at 99 
higher Pep-1 ratios (1:5, 1:10 and 1:15). A similar effect can be seen in the 1:15 ratio of NfnB-Cys 100 
conjugated with HR9, although it is not as pronounced as the effect seen with Pep-1.  101 
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Figure 2. Agarose gels of the NfnB-Cys enzyme conjugated with HR9 (left) and Pep-1 (right). Gels 103 
have unconjugated NfnB-Cys in lane 1, increasing ratios of NfnB-Cys:CPP in lanes 2, 3, 4, 5, 6, and 7 104 
of 1:0.1, 1:0.2, 1:1, 1:5, 1:10, and 1:15 respectively, and unconjugated CPP in the lane 8.  105 
2.3. NfnB-Cys and NfnB-Cys:CPP conjugate reactivity to CB1954 106 
The genetically modified NfnB-Cys enzyme reactivity towards the prodrug CB1954 has 107 
previously reported by Gwenin et al. [14,39]. The addition of a Cys-tag was shown not to negatively 108 
affect enzymatic activity [28], but the conjugation of the CPPs onto the NfnB-Cys may influence 109 
enzyme reactivity towards CB1954. For this reason NfnB-Cys:CPP conjugates were analysed for their 110 
CB1954 reactivity and compared relative to the free NfnB-Cys enzyme, the data for which is 111 
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Figure 3. The change in absorbance at 420 nm over 15 minutes for NfnB-Cys conjugated with varying 114 
ratios of HR9 (blue) or Pep-1 (orange) (wt:wt). The reactions were carried out in the presence of 115 
NADH (1,200 µM) and CB1954 (1,000 µM). 116 
When NfnB-Cys was conjugated with HR9 at varying ratios, hydroxylamine product formation 117 
could still be seen at 420 nm, however, there appeared to be a significant effect on product formation 118 
at ratios above 1:1. The experiment was repeated for NfnB-Cys:Pep-1 conjugates and no major effect 119 
on product formation was seen for all ratios tested. Kinetic parameters were then determined by 120 
generating a Michaelis-Menten profile for the conjugates (Table 1).  121 
Table 1. Michaelis-Menten kinetic data obtained for NfnB-Cys and the conjugated NfnB-Cys with 122 
HR9 and Pep-1 by varying the concentrations of the CB1954 prodrug in the presence of NADH as the 123 
cofactor. 124 
Conjugate Vmax (µMs-1) Kcat (s-1) Km (µM) Kcat/Km (µM-1s-1) 
NfnB-Cys:HR9 7.98 ±1.39 9.06 ±0.82 3443 ±916 0.00263 ±4.6x104 
NfnB-Cys:Pep-1 7.43 ±1.25 8.44 ± 0.73 2381 ±695 0.00354 ±6.5x104 
The comparison of the NfnB-Cys:CPP conjugates with our previously reported free NfnB-Cys 125 
enzyme kinetics [29], indicated an alteration in the enzyme’s kinetic behaviour, for both NfnB-126 
Cys:CPP conjugates. The kcat and Km values presented are the apparent (app) values measured at 400 127 
µM NADH. The CPPs decreased efficiency of NfnB-Cys; kcat/Km = 0.0026 µM-1s-1 for NfnB-Cys:HR9 128 
and 0.0033 µM-1s-1 for NfnB-Cys:Pep-1, compared to kcat/Km= 0.011 µM-1s-1 for NfnB-Cys). The reaction 129 
parameters had to be modified to use a higher concentration of NfnB-Cys:HR9/Pep-1 to obtain full 130 
kinetic profiles of the conjugates, due to prodrug cost, therefore only the kcat/Km constant can be 131 
directly compared between the NfnB-Cys enzyme and the NfnB-Cys:CPP conjugates. In comparison 132 
the NfnB-Cys:HR9 shows a slightly higher product turnover compared to the NfnB-Cys:Pep-133 
1conjugate (kcat(app)= 9.1 s-1 and 8.4 s-1 respectively), however, the NfnB-Cys:Pep-1 demonstrates a 134 
higher affinity than NfnB-Cys:HR9 for the CB1954 (Km(app) = 2400 µM and 3400 µM respectively). 135 
These results show that when conjugated to the CPPs; HR9 and Pep-1 at a 1:1 ratio NfnB-Cys has a 136 
65-74 % decrease in kinetic efficiency. These results are presented in table 1. 137 
2.4. HPLC profiles of NfnB-Cys and NfnB-Cyse:CPP reaction products  138 
Previously we have shown that after a 30 min reaction time, NfnB-Cys reduced CB1954 to 2 139 
products (namely 2-NHOH and 4-NHOH) at a ratio of 32:68 respectively [29]. Following the same 140 
procedure, conjugates of NfnB-Cys and the CPPs at a 1:1 molar ratio were tested for their ability to 141 
reduce CB1954. Reaction product ratios were established, with the 4-NHOH product eluting at 142 
approximately 5 min and the 2-NHOH eluting at 10 min [29,39]. The product ratios obtained for the 143 
reactions between NfnB-Cys:CPP conjugates and CB1954 are presented in table 2; the NfnB-Cys:HR9 144 
produced products at a ratio of 36:64 (2’-NHOH vs 4’-NHOH), whilst the NfnB-Cys:Pep-1 produces 145 
the 2-NHOH and 4-NHOH at a ratio of 35:65.  146 
Table 2. The ratio of the CB1954 hydroxylamine derivatives formed when NfnB-Cys:CPP conjugates 147 
were reacted with CB1954 in the presence of NADH as determined by HPLC. 148 
Conjugate Ratio (2-NHOH:4-NHOH) 
NfnB-Cys:HR9 36:64 
NfnB-Cys:Pep-1 35:65 
2.5. Effect of NfnB-Cys and NfnB-Cys:CPP conjugate on cell viability 149 
Cell viability of SK-OV-3 cells presented as percentage cell survival was determined using an 150 
increasing concentration of NfnB-Cys and NfnB-Cys:CPP conjugate and a constant CB1954 151 
concentration (10 µM). Cells were incubated with medium, prodrug and enzyme separately as 152 
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controls. NfnB-Cys was tested for its ability to induce cell death by the reduction of CB1954. This 153 
combination showed an average cell viability of 80% at an NfnB-Cys treatment concentration of 200 154 
nM, with the full results shown in figure 4. Next, the NfnB-Cys:HR9 and NfnB-Cys:Pep-1 conjugates 155 
were also tested for their ability to cause cell death, and compared relative to free NfnB-Cys, again 156 
full results are displayed in figure 4.  157 
 158 
Figure 4. The percentage cell survival of SK-OV-3 cells after 4 hr incubation with; cell culture medium 159 
only, 10 µM CB1954 only, 200 nM NfnB-Cys only, 200 nM NfnB-Cys:CPP only and increasing 160 
concentrations of either; NfnB-Cys (blue), NfnB-Cys:HR9 (orange) or NfnB-Cys:Pep-1 (grey) (25-200 161 
nM) in the absence of NADH. Data points determined to be statistically significant by Dunnett test 162 
are marked with a *. All data points represent at least 3 repeats and error bars indicate ± 1 standard 163 
deviation. 164 
At each concentration tested the NfnB-Cys:HR9 conjugates (25 nM-200 nM) appear to be more 165 
effective at causing cell death compared to NfnB-Cys alone (on average by 15%).Neither Pep-1 nor 166 
HR9 CPPs conferred any direct cytotoxicity towards SK-OV-3 cells. These results suggest that    167 
NfnB-Cys conjugates exhibited a greater endocytotic potential, because, as shown from the kinetic 168 
experiments, cell kill could not be attributed to enhanced enzyme efficiency. The data was analysed 169 
for statistical significance by F-test with all data sets demonstrating levels of statistical significance 170 
(P<0.005), with the individual data points being analysed using the Dunnett test. Data points marked 171 
with a *, exceeded the Dunnett critical value indicating statistical significance. 172 
2.6. Effect of AuMNPs and AuMNP conjugates on cell viability 173 
NfnB-Cys has been shown to successfully conjugate onto AuNPs [14], therefore it was 174 
considered highly probable the same would be observed when conjugating onto AuMNPs. 175 
Conjugation of NfnB-Cys onto AuMNPs was assessed by UV-Vis, figure 5 is the overlay of UV-vis 176 
scans between 450 and 650 nm. Here it is observed that post conjugation the λ-max of the gold peak 177 
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 179 
Figure 5. Full spectrum (450-650 nm) UV-vis spectrum of AuMNPs before (blue) and after (orange) 180 
conjugation with NfnB-Cys at a ratio of 1:270 of AuMNP:NfnB-Cys. Scans were taken 48 hours apart. 181 
There was concern that performing the MTT assay on the AuMNPs that any exposed iron 182 
nanoparticles would cause excess oxidation of the MTT yielding a bias on the final cell viability 183 
percentage [40,41]. A brief experiment was performed to assess if the AuMNPs would cause excess 184 
oxidation of the MTT causing a result bias. The AuMNPs caused a large excess of oxidation of the 185 
MTT indicating a different cell culture assay would be required (data not shown). Due to this the 186 
calcein assay was selected as it requires the use of cellular esterase’s to convert Calcein-AM into the 187 
fluorescent Calcein, an initial test showed the AuMNPs are not able to reduce Calcein-AM to Calcein 188 
indicating the assay could be used without the risk of an experimental bias (data not shown). Figure 189 
6 is the cell viability results of cells treated with: AuMNPs, AuMNP:NfnB-Cys or       190 
AuMNP:NfnB-Cys:HR9, here the range of concentrations examined are the same as the cell viability 191 
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 193 
Figure 6. The percentage cell survival of SK-OV-3 cells after 4 hr incubation with; cell culture medium 194 
only, 10 µM CB1954 only, 200 nM AuMNP only, 200 nM AuMNP:NfnB-Cys only or 200 nM 195 
AuMNP:NfnB-Cys:CPP only as control wells. Reaction wells contained increasing concentrations of 196 
either; AuMNP (blue), AuMNP:NfnB-Cys (orange) or AuMNP:NfnB-Cys:HR9 (grey) (25-200 nM) in 197 
the absence of NADH. Complete reactions also contain CB1954 at a 10 µM concentration. All data 198 
points represent at least 3 repeats and error bars indicate ± 1 standard deviation. 199 
The AuMNPs do not demonstrate any direct toxicity towards the SK-OV-3 cells. As expected 200 
when AuMNP:NfnB-Cys and AuMNP:NfnB-Cys:HR9 conjugates were treated onto cells, there was 201 
cell kill, which was taken to be the NfnB-Cys reducing the CB1954 due to the lack of toxicity presented 202 
in the conjugated control samples. Here once again the conjugates with the HR9 do present a slightly 203 
better cell kill overall than the AuMNP: NfnB-Cys, however the increase in the cell kill is minimal at 204 
best. The data was analysed for statistical significance by F-test with all data sets demonstrating levels 205 
of statistical significance (P<0.005). The Dunnett test could not be performed to determine individual 206 
data points statistical significance due to the low number of concentrations tested. 207 
2.7. Darkfield imaging 208 
Enhanced Darkfield imaging was performed on SK-OV-3 cells treated with either: DMEM, 209 
AuMNP, AuMNP:NfnB-Cys or AuMNP:NfnB-Cys:HR9, with the HR9 at a 1:1 ratio with the AuMNP. 210 
Treatments were done to assess cell uptake of the nanoparticle/nanoparticle conjugates and if the 211 
addition of the HR9 aided in increasing cellular uptake. On the basis that the HR9 conjugates 212 
appeared to be superior in cell culture testing as an isolated conjugate, only the NfnB-Cys:HR9 213 
combination was progressed to AuMNP testing. Figure 7 is the enhanced Darkfield imaging of these 214 
slides, figure 7A is the imaging of cells treated with just DMEM to act as a control, with the cell 215 
nucleus stained blue with DAPI. The untreated control cell (panel A) acts as a negative in relation to 216 
AuNP internalisation, to which any changes in terms of particle intensity are compared following 217 
treatment with AuMNPs. Figure 7B, 7C and 7D are images taken of cells treated with AuMNP, 218 
AuMNP:NfnB-Cys or AuMNP:NfnB-Cys: HR9 respectively, again the cell nuclei are counterstained 219 
blue with DAPI. These images have a higher frequency of intense areas within the cells, which are 220 
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cells. The increased bright areas within the cells in the images indicate that the AuMNPs have 222 
internalized into the SK-OV-3 cells and when conjugated with NfnB-Cys, has an increase in 223 
internalized nanoparticles. However, the AuMNP has a significant enhancement in nanoparticle 224 
internalization when conjugated with a CPP, shown in figure 7D. 225 
 226 
Figure 7. Enhanced Darkfield imaging of cells treated with either: DMEM, AuMNP, AuMNP:NfnB-227 
Cys or AuMNP:NfnB-Cys:HR9, with the images for each presented in figure 7A, 7B, 7C and 7D 228 
respectively. The cells were treated with DAPI as a co-stain for imaging of the cell nucleus. The scale 229 
bar is 25 µm. 230 
3. Discussion 231 
Since their initial discovery in 1988 CPPs have presented as a unique tool for aiding in the uptake 232 
and delivery of a range of cargoes for medical applications. Literature shows that CPPs bind       233 
non-covalently to specific cargo [36,42–44], the initial work was to determine whether HR9 and    234 
Pep-1 could also non-covalently conjugate with our enzyme as a majority of other studies focus on 235 
conjugation with inorganic substances such as quantum dots. Conjugation success was confirmed, 236 
showing that both HR9 and Pep-1 conjugates significantly alter the electrophoretic migration of 237 
NfnB-Cys through the gel (figure 2 A and B) [45]. The HR9 peptide had a greater influence on    238 
NfnB-Cys migration, compared to Pep-1, possibly a result of possessing a greater positive charge, 239 
caused by the large number of cationic arginine residues [44], 9 of which are found in the HR9 CPP 240 
[36,46], compared with the 1 arginine residue found within the Pep-1 [46]. 241 
The high positive charges that CPPs possess could present a possible problem in terms of 242 
interactions with the physical structure of proteins, this becomes a potential issue for enzyme 243 
conjugation as it has previously been established that changes to the physical structure of the NfnB 244 
enzyme can cause a change in the product ratio formed when the enzyme is reacted with the CB1954 245 
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prodrug [28]. Analysis by HPLC of the product ratio formed for the NfnB-Cys:CPP conjugates 246 
showed little to no change from the free NfnB-Cys enzyme (ratio 32:68). NfnB-Cys:HR9 produced a 247 
ratio of 36:64, whilst NfnB-Cys:Pep-1 produced a ratio of 35:65. The fact that the CPPs do not heavily 248 
influence the product ratio formed here indicates that the CPPs are not causing any major alteration 249 
to the physical structure of the NfnB-Cys enzyme when they conjugate with it. This is important as 250 
it means that the enzyme can still convert the CB1954 into its pharmaceutically active form without 251 
CPP interference. A concern that would limit the efficiacy of this treatment is that the CPPs are non-252 
covalently bound with the AuMNP:NfnB-Cys conjugate, which could dissociate when introduced to 253 
a patient. Stability studies were carried out on AuMNP:NfnB-Cys:CPP conjugates (data not shown) 254 
in the cell culture media used in the experiments discussed in this paper. The conjugates were left at 255 
37°C to simulate physiological conditions and were stable at up to and including 120 hours which 256 
would be a semi-realistic representation of treatment time. 257 
As seen from the HPLC experiment, conjugated CPPs had no real effect on the product ratio of 258 
NfnB-Cys, however, establishing if CPP conjugation caused an alteration in enzyme kinetics was 259 
essential before progressing. As mentioned in section 2.3 only the efficiency constant (kcat/Km µM-1s-1) 260 
can be directly compared between the free and conjugated NfnB-Cys. When looking at the Kcat/Km of 261 
the free NfnB-Cys, a value of 0.018 µM-1s-1 has previously been reported [29]. Both the kcat/Km values 262 
for the NfnB-Cys:CPP conjugates show a significant drop in their efficiency, with NfnB-Cys:HR9 263 
having a value of 0.0026 µM-1s-1 which is 4-fold less than NfnB-Cys and NfnB-Cys:Pep-1 having a 264 
kcat/Km of 0.0035 µM-1s-1, a value almost 3-fold lower than NfnB-Cys. Therefore, while the earlier 265 
experiments showed very little change in both product ratio and product formation, the efficiency of 266 
both conjugates and product turnover has dramatically reduced compared to free NfnB-Cys. It is 267 
likely that the change in enzymatic efficacy is not detected in the earlier experiments as UV-Vis 268 
absorbance measurements were collected at 15 min, and the HPLC reaction time point was 30 min. 269 
However, enzymatic kinetic experiments captured a short time frame, calculated over a 20 sec time 270 
period. It is likely that whilst the shorter kinetic experiments represent an accurate kinetic picture of 271 
the enzyme, the longer experiments possibly indicate a more realistic scenario of the final 272 
concentration of products produced as it allows for full reduction and consumption of prodrug. This 273 
drastic change in efficiency of the conjugate compared to the free NfnB-Cys does raise a question that 274 
requires further research to understand: if the HPLC indicates that the ratio of products formed does 275 
not largely differ from the ratio formed by the free NfnB-Cys why does the kinetic data show such a 276 
difference? This might indicate that the CPPs have some sort of interaction with the active site of the 277 
NfnB-Cys, it may be that there is some slight blockage of the active site, or the CPPs cause a delay in 278 
the release of the products from the active site. Further experiments are needed to answer this 279 
anomaly in the data. 280 
When examining the NfnB-Cys:CPP conjugates in cell viability assays, there is an observable 281 
improvement in the ability of the NfnB-Cys:CPP conjugates to induce cell death over free NfnB-Cys. 282 
No additional NAD(P)H was added during the experiments, this was done so that the only cofactor 283 
available for the enzyme would be found intracellularly within the SK-OV-3, meaning that the 284 
enzyme has to be internalized along with the CB1954 to reduce the prodrug. This increased cell death, 285 
indicates that the addition of CPPs onto the enzyme aids the uptake of the enzyme, allowing the 286 
increased cell kill despite the lowered enzymatic efficiency observed.  The lower concentration range 287 
of NfnB-Cys:HR9 tested in cell culture presents a low cell viability, this can be potentially attributed 288 
to the hormetic effect [47], and may indicate a treatment concentration of 25 nM      NfnB-Cys:HR9 289 
as a better option compared to the 200 nM treatment concentration. 290 
The NfnB-Cys is intended for use in our patented MNDEPT [27], so in order to assess cellular 291 
uptake of the enzyme, it was covalently conjugated to the AuMNPs and assessed for its viability as a 292 
delivery vector, further conjugating HR9 with the AuMNP:NfnB-Cys and measuring the ability to 293 
cause cell death. The cell viability results of the AuMNP trials presented in figure 6 indicate that the 294 
AuMNPs and the AuMNP conjugates do not themselves have an adverse toxic effect on the SK-OV-295 
3 cells, from this it can be reasoned that any cell kill present is from the AuMNPs/AuMNP conjugates 296 
that are able to internalize into the cells along with CB1954. Both of the conjugates tested were able 297 
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to reduce CB1954, shown by the decrease in cell viability which became more pronounced with the 298 
increasing concentration dose.  299 
At each concentration tested, the conjugate with HR9 attached does show an increase in the cell 300 
kill. However this increase is very small, at a maximum 5-10%. This may indicate that either the ratio 301 
of HR9 used for the treatment needs to be increased to achieve a higher internalization rate of 302 
conjugates. It can also indicate that HR9 is not able to effectively internalize the AuMNP, meaning a 303 
different CPP might present as a better option. It is also possible that all the cell culture data has 304 
varying degrees of endosomal trapping preventing the enzyme from fully reducing the prodrug 305 
within the cells, in which case the CPPs may need slight modification to achieve endosomal escape 306 
either with the use of an endosomolytic agent or a way to reverse high-affinity binding to cell 307 
receptors [48]. Furthermore uptake efficiency of CPPs into cells can vary based on cell type, here the 308 
cell line SK-OV-3 showed CPP uptake, however it must be considered that other cell types may show 309 
much more limited uptake or no uptake at all. Along with this further work to be done would involve 310 
examining the potential lysosomal trapping and to assess colocalization of the nanoparticle 311 
conjugates within the cellular structures. 312 
Darkfield imaging was performed on the 3 nanoparticle/ nanoparticle conjugates to assess if the 313 
conjugation of either the NfnB-Cys and/ or the HR9 increases the cellular internalization of the 314 
nanoparticle. Darkfield imaging allows us to visually inspect cells, and view nanoparticles that are 315 
associated within the cell, here imaging was performed in an attempt to assess what observable 316 
change, if any, the addition of a CPP onto the conjugate had on the cellular internalization of the 317 
conjugate. It is observable that the addition of the NfnB-Cys onto the AuMNP causes more 318 
nanoparticles to internalize into the cells, compared with unconjugated AuMNP. This is important 319 
as it shows that even without the CPP, the AuMNP:NfnB-Cys conjugate can penetrate into the cells,   320 
reinforcing that AuMNPs are a viable choice for use in MNDEPT. The more notable difference is 321 
observed with the incorporation of a CPP onto the conjugate. This addition allows a drastically larger 322 
number of conjugates to internalize into the cells, indicating that the CPP is being successful in its 323 
role.   324 
In conclusion, two different CPPs have been successfully conjugated to the genetically modified 325 
NfnB-Cys enzyme at a 1:1 ratio. The HPLC reaction profiles of the NfnB-Cys:CPP conjugates have 326 
been described, showing a slight change from the ‘free’ NfnB-Cys enzyme’s product ratio. Kinetic 327 
profiles have been established for the conjugates at a 1:1 ratio showing a large drop in the conjugates 328 
kinetic efficiency. However, when the conjugates are tested in cell viability assays an increased cell 329 
kill is observed, consistent with what would be expected with an increased uptake of the enzyme, 330 
whilst the CPPs themselves show no observable toxicity. Cell viability assays were also performed 331 
on AuMNP, AuMNP:NfnB-Cys and AuMNP:NfnB-Cys:HR9 conjugates, the AuMNPs themselves 332 
had no observable toxicity towards the cells whilst the other tested conjugates demonstrated an 333 
increasing cell kill with increasing treatment concentration. Finally Darkfield imaging presents an 334 
increased internalization of AuMNP conjugated when HR9 is also conjugated with the 335 
AuMNP:NfnB-Cys, which is consistent with the increase cell kill seen on the AuMNP:NfnB-Cys:HR9 336 
conjugate. 337 
4. Materials and Methods  338 
All chemicals were supplied from Fisher Scientific, UK and Sigma Aldrich, UK unless stated 339 
otherwise. 340 
4.1. Expression and purification 341 
A nfnb-cys gene that had been previously cloned into the pET28a(+) (Novagen, Merck, UK) 342 
expression vector [14], was transformed into an E.coli Rosetta strain B21 DE3 (Novagen, Merck UK) 343 
and the expression and purification of the NfnB-Cys enzyme was carried out as previously described 344 
[14]. Briefly, a colony of E. coli Rosetta containing the expression vector (previously confirmed using 345 
gel electrophoresis –data not shown-) with the nfnb-cys gene was added to a Luria-Bertani (LB) 346 
inoculant tube (5 ml) also containing kanamycin (50 µg/ml). This was vortexed at 1500 rpm overnight 347 
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for 16 hours. Following this the inoculant was added to a flask containing LB expression medium 348 
(500 ml) and kanamycin (50 µg/ml). The bacterial medium was left to grow to an optical density of 349 
0.6-0.7 measured at 590 nm, after which expression of protein was induced by the addition of      350 
isopropyl-β-D-thio-galactoside (IPTG) (2 ml, 100 mM). After 4 h of NfnB-Cys expression, the culture 351 
was centrifuged (9318 rcf, 10 min, 4oC) and cell contents released by firstly suspending the bacterial 352 
pellet in imidazole (10 mM, pH 7.2) and then sonicated on ice for 2 min at 40% amplitude, using 30 353 
sec bursts. Cell debris was removed by high-speed centrifugation (44,800 rcf, 1 h) and the yellow 354 
supernatant passed through a metal ion affinity chromatography column using Ni2+, with imidazole 355 
as the eluent. NfnB-Cys protein eluted as yellow fractions that were collected and incubated with 356 
flavin mononucleotide (FMN) on ice for 1 h to ensure cofactor saturation. The saturated solution was 357 
then subjected to PD10 size exclusion chromatography (SEC) to remove both impurities and any 358 
residual imidazole eluent, before the NfnB-Cys enzyme was collected in phosphate buffer (50 mM, 359 
pH 7.2). The molecular weight and purity of the protein fractions were assessed using 12% SDS-360 
PAGE and visualized using Coomassie blue stain. The concentration of the protein was established 361 
using the Bradford assay using a standard BSA curve, according to the manufacturer’s instructions. 362 
4.2. CPP conjugation to NfnB-Cys 363 
Conjugation of the CPPs, HR9 (CHHHHHHRRRRRRRRRHHHHHHC) and Pep-1 364 
(KETWWETWWTEWSQPKKKRKV), to the NfnB-Cys enzyme was performed as described for 365 
conjugation onto quantum dots (QD) by Liu et al.[36], and replacing the QD with our NfnB-Cys. This 366 
was done by mixing the enzyme and CPP in a silinated Eppendorf at various wt:wt ratios (1:0.1, 1:0.2, 367 
1:1, 1:5 1:10, 1:15). The enzyme: CPP mix was then incubated at 37oC for 30 min and assessed for 368 
conjugation via agarose gel electrophoresis.  369 
4.3. Confirmation of CPP conjugation to NfnB-Cys 370 
A 1% (w/v) agarose gel was prepared by dissolving agarose (1 g) in 100 ml TBE buffer (Tris-HCl; 371 
54 g, Boric acid; 27.5 g, EDTA; 20 ml, 500 mM dissolved in H2O 1 L, pH 8) [14]. The gel was then 372 
submerged in 1 X TBE running buffer and the comb removed. NfnB-Cys:CPP conjugate (20 µl) was 373 
mixed with 20 µl of a 2x loading dye (10 mM Tris-HCl pH 6.8, 2% SDS, 0.01% Bromophenol blue, 374 
20% glycerol) [45,49] and loaded onto the gel. Unconjugated NfnB-Cys and CPP were used as 375 
controls. The gel was then run at 100 V for 1 h, and visualized using Coomassie blue stain. 376 
4.4. NfnB-Cys and NfnB-Cys:CPP conjugate activity to CB1954 377 
NfnB-Cys:CPP conjugates and unconjugated NfnB-Cys were assessed for their reactivity to 378 
CB1954 by incubating NfnB-Cys (25 µg/ml) or NfnB-Cys:CPP (25 µg/ml, with volume added adjusted 379 
for additional CPP in the mixture to ensure 25 mg/ml of NfnB-Cys) with NADH (300 µM), Phospahte 380 
buffer (PB) (50 mM, pH 7.2) and CB1954 (100 µM). Absorbance spectra (200- 800 nm) were measured 381 
every 90 s for 15 min on a Jasco V-550, UV/vis spectrophotometer. Standard control scans were also 382 
run on the NADH, enzyme, enzyme:CPP conjugate, prodrug and CPP with NADH and CB1954 to 383 
ensure the CPPs could not reduce the prodrug. 384 
4.5. CB1954 Kinetics 385 
CB1954 kinetic experiments were all carried out in a 96-well microtiter plate (Corning, USA) 386 
using a Thermoscientific Varioskan 96-well plate microplate reader [29]. Product formation at 420 nm 387 
was measured over time in order to determine the Michaelis-Menten kinetic parameters of CB1954 388 
against the NfnB-Cys:CPP conjugate. CB1954 (0.1-5 mM), NADH (400 µM) and PB (50 mM, pH 7.2) 389 
were combined and incubated at 37oC for 3 min before purified NfnB-Cys or NfnB-Cys:CPP (1:1 ratio)  390 
was added (50 μg/ml; again NfnB-Cys:CPP volume added was adjusted to ensure 50 μg/ml of  NfnB-391 
Cys was added). Dimethyl sulfoxide (DMSO) solvent concentration was kept constant at 5% v/v to 392 
account for any negative solvent related effect [50]. Hydroxylamine yield per second was determined 393 
by calculating the change in absorbance over 20 seconds and the molar extinction coefficient, which 394 
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is the same for both products (ε = 1200 M-1 cm-1 at 420 nm) [14,18,39,50–53]. Data gathered was 395 
transferred to SigmaPlot 12 (SPSS, Systat Software Inc.) where a non-linear regression tool was used 396 
to generate a Michaelis-Menten hyperbolic curve and a report containing the kinetic information of 397 
the system. 398 
4.6. HPLC  399 
For HPLC analysis, a Dionex Ultimate 3000 HPLC machine Thermoscientific, USA was used 400 
with a C18 column (Waters Spherisorb® 5 µm ODS2 4.6 mm x 250 mm C18 column, UK). Experiments 401 
were carried out at the following parameters: 50 µl injection volume, 25oC column oven temperature, 402 
UV detection wavelength of 420 nm and a run time of 30 min [41,42]. 403 
HPLC samples were prepared as previously described [29,39]. Briefly; samples were prepared 404 
in a 15 ml amber falcon tube (due to the light sensitive nature of some of the reaction constituents) as 405 
follows: NADH (120 µl, 10 mM) NfnB-Cys/ NfnB-Cys:CPP (116 µg/ml, volume adjusted), CB1954 (20 406 
µl, 50 mM) then made to a final volume of 1080 µl using PB (50 mM, pH 7.2). This mixture was 407 
incubated at 25oC for 15 min, and then degassed under nitrogen (g) for 15 min, giving a total reaction 408 
time of 30 min. Next, 750 µl of the final de-gassed reaction was transferred to a chromacol select 2 ml 409 
vial (2-SVW8-CPK) and placed into the HPLC machine. The solvent mixture was acetonitrile/water 410 
at a 10:90 ratio, with the acetonitrile increasing at 1% per min. After 20 min the acetonitrile 411 
concentration was altered to keep increasing by 40% per minute which reached a concentration of 412 
100% acetonitrile after 22 min. Eluents were scanned at 420 nm with product peaks being identified 413 
against reagent standards carried out using the same protocol: CB1954 (20 µl, 50 mM), NADH (120 414 
µl, 10 mM) NfnB-Cys (116 µg/ml, volume adjusted for concentration of NfnB-Cys from purification). 415 
Ratios of the 2’ and 4’-hydroxylamine products were determined at 420 nm, where both products 416 
have equal absorbance [18].  417 
4.7. Cell viability assays 418 
Cell viability assays were performed as previously described [30]. SK-OV-3 (ECACC 91091004) 419 
cells were seeded into a 96-well plate (Corning, USA) at a density of 1 x 103 cells per well, in 100 µl 420 
Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS, 1% L-glutamine and 1%   421 
penicillin-streptomycin and allowed to attach to the plate overnight in a CO2 (5%) incubator at 37oC. 422 
After 16 h, the media was carefully aspirated off and fresh media containing increasing 423 
concentrations of 25 nM to 200 nM of NfnB-Cys or NfnB-Cys:CPP conjugate (50 µl) was added to the 424 
wells along with CB1954 (100 µM). Wells where only NfnB-Cys, NfnB-Cys:CPP conjugate (200 nM), 425 
CB1954 (10 µM) or DMEM (100 µl) were added served as controls. After a 4 h incubation in a CO2 426 
(5%) incubator at 37oC, the treatment media was carefully aspirated off and fresh media (100 µl) 427 
added. Cells were then left for 48 h in a CO2 (5%) incubator at 37oC, after which MTT (3-(4,5-428 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (20 µl, 5 mg/ml) was added and then left for 429 
a further for 4 h at 37oC. Culture media was aspirated off and DMSO (100 µl) used to dissolve the 430 
purple formazan crystals. Finally, absorbance was read at 570 nm using a Thermoscientific Varioskan 431 
Flash plate reader.  432 
4.8. Preparation of AuMNP:NfnB-Cys and AuMNP:NfnB-Cys:HR9 conjugates for cell culture and 433 
Darkfield imaging 434 
Previously synthesised AuMNPs [43] were conjugated with NfnB-Cys following the published 435 
method for conjugating NfnB-Cys onto gold nanoparticles [14]. Briefly, magnetically purified, 50 nm 436 
AuMNPs suspended in sodium citrate dehydrate (1 mM, pH 7.4) were incubated with a volume of 437 
NfnB-Cys at a ratio of 1 AuMNP:270 NfnB-Cys to achieve a monolayer coating of the nanoparticles. 438 
The volume of NfnB-Cys incubated with AuMNPs was determined based upon the concentration of 439 
NfnB-Cys determined by the Bradford assay and the concentration and size of AuMNPs as 440 
determined by UV-Vis [14]. Nano-conjugates were left to form at 4oC for 48 h. A full wavelength  441 
UV-Vis scan (450-650 nm) was performed on AuMNPs before and after conjugation, with a change 442 
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in the gold peak being examined for. A red shift of 3-5 nm of the λ-max of the gold peak indicates 443 
successful conjugation [14,55]. AuMNP:NfnB-Cys:HR9 conjugates were prepared by incubating the 444 
AuMNP:NfnB-Cys with HR9 at a 1:1 ratio of HR9 to AuMNP, at 37oC for 30 min. 445 
4.9. AuMNP cell viability assays 446 
The Calcein assay was performed of AuMNPs and AuMNP conjugates. SK-OV-3 (ECACC  447 
91091004) cells were seeded into a 96-well plate (Corning, USA) at a density of 1 x 103 cells per well, 448 
in 100 μl Dulbecco’s Modified Eagle Medium (DMEM) containing 10% FBS, 1% L-glutamine and 1% 449 
penicillin-streptomycin and allowed to attach to the plate overnight in a CO2 (5%) incubator at 37oC. 450 
After 16 h, the media was carefully aspirated off and fresh media containing increasing 451 
concentrations of 25 nM to 200 nM of AuMNPs, AuMNP:NfnB-Cys or AuMNP:NfnB-Cys:HR9 (50 452 
µl) was added to the wells along with CB1954 (100 µM). Wells where only, AuMNP, AuMNP:NfnB-453 
Cys AuMNP:NfnB-Cys:CPP conjugate (200 nM), CB1954 (10 µM) or DMEM (100 µl) were added 454 
served as controls. After a 4 h incubation in a CO2 (5%) incubator at 37oC, the treatment media was 455 
carefully aspirated off and fresh media (100 µl) added. Cells were then left for 48 h in a CO2 (5%) 456 
incubator at 37oC, after which the media was carefully aspirated off and 1X Calcein DW buffer (100 457 
µl) was added to each well. This was again carefully aspirated off after which 1X Calcein DW buffer 458 
(50µl) and 2X Calcein AM (50µl) were added to each well. The plate was then incubated for 30 459 
minutes in a CO2 (5%) incubator at 37OC. The fluorescence of the sample was measured using an 460 
excitation/emission filter of 495/515 nm using a Thermoscientific Varioskan Flash plate reader.  461 
4.10. Darkfield Imaging 462 
Darkfield imaging was performed using CytoViva enhanced Darkfield imaging. SK-OV-3 cells 463 
were seeded onto 8-well Thermo Scientific™ Nunc™ Lab-Tek™ II Chamber Slide&trade glass slides 464 
at a density of 1 x 104 cells per well. Sub-confluent cells (~80%) were treated with either DMEM media 465 
as a control, unconjugated/ ‘naked’ AuMNPs, AuMNP conjugated with NfnB-Cys at a ratio of 1:270 466 
of AuMNP:NfnB-Cys, or AuMNP:NfnB-Cys conjugated with HR9, with the CPP conjugated at a ratio 467 
of 1:1 with the AuMNP:NfnB-Cys conjugates. Cells were incubated with complexes for 4 h before the 468 
treatment media was removed and cells washed twice with DPBS, removing loosely associated  469 
external nanoparticles [56–60]. Cells were then fixed using 3.7% formaldehyde and mounted using 470 
Vectashield containing 4′,6-diamidino-2-phenylindole (DAPI) (Vector labs), counterstaining the 471 
nucleus.  472 
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